Lav initial dosis anbefales for at minimere risikoen for forværring af paniksymptomerne, hvilket er generelt anerkendt at forekomme tidligt i behandlingen af denne tilstand.
A low initial starting dose is recommended to minimise the potential worsening of panic symptomatology, which is generally recognised to occur early in the treatment of this disorder.